VivoSim Labs, Inc. (NASDAQ: VIVS) shares gained ground Wednesday. The company, a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for preclinical safety, today announced revenue guidance for FY2027, and announced that it has received a $5-million payment from Eli Lilly.
In association with its former inflammatory bowel disease drug program developed previously and sold outright to Eli Lilly, VivoSim has received $5 million as a milestone payment. The payment represents the dosing of the first patient in Phase 2 studies of the drug in Eli Lilly’s development program.
The drug’s development is entirely guided by Eli Lilly, but VivoSim remains eligible for up to $45 million in additional milestone payments over time as the drug is developed and commercially marketed, provided it is able to hit key regulatory and commercial milestones.
VivoSim further announced that it anticipates significant revenue growth in Fiscal Year 2027 given its progress in marketing contract research services using NAMs models to pharmaceutical companies. The company anticipates over 500% revenue growth in the fiscal year, due to customer response to the predictive power of its NAMs models, which are building traction with a wide set of customers.
VIVS shares picked up 16 cents, or 19.8%, to one dollar.
